While ID is one of the most frequent complications inducing ESA-resistant anemia among patients with end-stage renal disease (ESRD), a substantial proportion of patients exhibit ID with target Hb levels. This evidence concerns the gene GSTM1 and stage 5 chronic kidney disease.